Kyomarc
Application withdrawn
The application for this medicine has been withdrawn
bevacizumab
MedicineHumanApplication withdrawn
- Application under evaluation
- Withdrawal of application
Overview
On 17 October 2017, Amgen Europe BV officially notified the Committee for Medicinal Products for Human Use (CHMP) that it wishes to withdraw its application for a marketing authorisation for Kyomarc, for the treatment of cancer of the colon or rectum, breast cancer, non-small cell lung cancer (NSCLC), kidney cancer, cervical cancer, and cancer of the ovary, the fallopian tube, or the peritoneum.
Kyomarc is a cancer medicine that contains the active substance bevacizumab. It was to be available as a concentrate to be made up into a solution for infusion (drip) into a vein.
Kyomarc was developed as a 'biosimilar' medicine. This means that Kyomarc was intended to be highly similar to another biological medicine (the 'reference medicine') already authorised in the EU. The reference medicine for Kyomarc is Avastin.
Kyomarc was to be used to treat cancer of the colon or rectum, breast cancer, NSCLC, kidney cancer, cervical cancer, and cancer of the ovary, the fallopian tube, or the peritoneum.
Kyomarc was expected to work in the same way as the reference medicine, Avastin. The active substance in Kyomarc and Avastin, bevacizumab, is a monoclonal antibody (a type of protein) that has been designed to recognise and attach to vascular endothelial growth factor (VEGF), a protein that circulates in the blood and makes blood vessels grow. By attaching to VEGF, bevacizumab stops it having an effect. As a result, the cancer cells cannot develop their own blood supply and are starved of oxygen and nutrients, helping to slow down the growth of tumours.
The company presented laboratory studies comparing Kyomarc to its reference medicine Avastin in terms of its structure, purity and biological activity. A study in 202 healthy volunteers compared Kyomarc with Avastin to determine whether the two medicines produce similar levels of the active substance in the body. In addition, a study in 642 patients with advanced NSCLC compared the effectiveness and safety of Kyomarc and Avastin.
The application was withdrawn after the CHMP had evaluated the documentation provided by the company and formulated lists of questions. The CHMP was assessing the company's responses to the last round of questions at the time of the withdrawal.
Based on the review of the data at the time of the withdrawal, the CHMP had no major concerns and was of the provisional opinion that Kyomarc could have been approved for the treatment of the cancers listed above.
In its letter notifying the Agency of the withdrawal of the application, the company stated that it was withdrawing the application for marketing reasons. The company said it will continue with its marketing authorisation application for another medicine, Mvasi, which is also a biosimilar medicine containing bevacizumab.
The company informed the CHMP that there are no ongoing clinical trials or compassionate-use programmes for this medicine.
Key facts
- Name of medicine
- Kyomarc
- Active substance
- bevacizumab
- International non-proprietary name (INN) or common name
- bevacizumab
- Therapeutic area (MeSH)
- Carcinoma, Renal Cell
- Carcinoma, Bronchogenic
- Fallopian Tube Neoplasms
- Breast Neoplasms
- Ovarian Neoplasms
- Peritoneal Neoplasms
- Anatomical therapeutic chemical (ATC) code
- L01XC07
- EMA product number
- EMEA/H/C/004360
- Marketing authorisation applicant
- Amgen Europe B.V.
- Withdrawal of application
- 17/10/2017
All documents
News on Kyomarc
This page was last updated on